Krónikus mieloid leukémia (CML): vizsgálatok itt: Németország
19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Erlangen, Frankfurt am Main, Hamburg
- Életkor
- 1 év to 18 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - 2. fázisTaking peopleEfficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
- Where
- Aachen, Berlin, Chemnitz, Hanover, Jena, Leipzig, Mannheim, Ulm
- Életkor
- 18 év and over
- People
- 50
- Run by
- Thomas Ernst, Prof. Dr. med.
See details and how to joinNCT07789574 · EU 2025-523491-23-00 - 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - No phaseTaking peopleA Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
- Where
- Altenburg, Amberg, Aschaffenburg, Augsburg, Baden-Baden, Bad Friedrichshall, Bad Liebenwerda, Bad Saarow, Berlin, Bremerhaven, Buchholz Nordheide, Cologne, Cottbus, Deggendorf, Detmold, Donauwörth, Dorfen, Dortmund, Dresden, Düren, Erfurt, Eschweiler, Goslar, Göttingen, Halle, Hanover, Heidenheim, Herrsching am Ammersee, Hildesheim, Kassel, Kempten (Allgäu), Kiel, Landsberg am Lech, Leipzig, Leverkusen, Merseburg, Munich, Mutlangen, Naunhof, Neuss, Offenbach, Offenburg, Oldenburg, Oldenburg in Holstein, Parchim, Potsdam, Regensburg, Rotenburg (Wümme), Saalfeld, Schorndorf, Schwäbisch Hall, Schwetzingen, Soest, Solingen, Stade, Torgau, Twistringen, Ulm, Wesel, Wetzlar, Winnenden, Zittau
- Életkor
- 18 év to 100 év
- People
- 380
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07549516 - 1. fázisTaking peopleA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Berlin, Munich, Ulm
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00 - 1/2. fázisTaking peopleA Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
- Where
- Aachen, Berlin, Frankfurt Am Main, Hanover, Jena, Mannheim, Munich
- Életkor
- 18 év to 64 év
- People
- 330 worldwide
- Run by
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
See details and how to joinNCT06163430 · EU 2023-507677-18-00 - 2/3. fázisTaking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg
- Életkor
- 18 év and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - 4. fázisTaking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
- Életkor
- 18 év and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00 - 1/2. fázisTaking peopleVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- Where
- Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich
- Életkor
- 18 év and over
- People
- 38
- Run by
- Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05807932 · EU 2024-514688-24-00 - 2. fázisTaking people(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Aachen, Freiburg im Breisgau, Lübeck, Mannheim
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - 3. fázisTaking peopleStudy of Olverembatinib (HQP1351) in Patients With CML-CP
- Where
- Berlin, Dresden, Leipzig
- Életkor
- 18 év and over
- People
- 333 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06423911 · EU 2024-511495-32-00 - 2. fázisNot yet taking people in NémetországAsciminib Frontline Risk Adapted
- Where
- Jena
- Életkor
- 18 év and over
- People
- 200
- Run by
- Prof. Dr. med. Andreas Hochhaus
See details and how to joinNCT07804901 · EU 2026-528103-13-00 - 2. fázisTaking peopleStudy to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
- Where
- Dresden, Erlangen, Essen, Frankfurt Am Main, Hamburg
- Életkor
- Up to 17 év
- People
- 16 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522138-29-00 · EU 2025-522138-29-00 - 2. fázisCsak meghívásosA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Brunswick, Luebeck
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - 1/2. fázisNot yet taking people in NémetországA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
- Where
- Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00 - 1. fázisTaking peopleA Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- Where
- Aachen, Berlin, Frankfurt Am Main, Homburg, Jena, Mannheim, Rostock
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Enliven Therapeutics
See details and how to joinNCT05304377 · EU 2023-503335-18-00 - 1. fázisCsak meghívásosLong-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
- Where
- Berlin, Dresden, Marburg, Munich, Ulm
- Életkor
- 18 év and over
- People
- 178
- Run by
- AvenCell Therapeutics, Inc.
See details and how to joinNCT07474051 · EU 2025-521717-67-00 - 1/2. fázisTaking peopleClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Berlin, Brunswick, Leipzig
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00 - No phaseTaking peopleInternational Chronic Myeloid Leukemia Pediatric Study
- Where
- Dresden
- Életkor
- Up to 18 év
- People
- 750 worldwide
- Run by
- Poitiers University Hospital
See details and how to joinNCT01281735